Vanda Scores FDA Approval For BYSANTI, Its Second Regulatory Nod In Less Than Two Months

Shares of Vanda Pharmaceuticals Inc. (VNDA) are up over 40% in after-hours trading on Friday, following a regulatory update..

You will be redirected in 10 seconds.